It took a leap of faith for researchers to believe that antisense technology might lead to novel medicines, but that commitment could soon pay off.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Inhibition of porcine reproductive and respiratory syndrome virus replication in vitro using DNA-based short antisense oligonucleotides
BMC Veterinary Research Open Access 12 August 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dove, A., Nat. Biotechnol. 18, 19 (2000).
Niiler, E., Nat. Biotechnol. 19, 898–899 (2001).
Tyler, B.M. et al. Proc. Natl. Acad. Sci. USA 96, 7053–7058 (1999).
Sayda, M.E. et al., Nature 411, 494–498 (2001).
Rights and permissions
About this article
Cite this article
Dove, A. Antisense and sensibility. Nat Biotechnol 20, 121–124 (2002). https://doi.org/10.1038/nbt0202-121
Issue Date:
DOI: https://doi.org/10.1038/nbt0202-121
This article is cited by
-
Inhibition of porcine reproductive and respiratory syndrome virus replication in vitro using DNA-based short antisense oligonucleotides
BMC Veterinary Research (2015)
-
Comparative studies of suppression of malignant cancer cell phenotype by antisense oligo DNA and small interfering RNA
Cancer Gene Therapy (2006)
-
siRNAs: applications in functional genomics and potential as therapeutics
Nature Reviews Drug Discovery (2004)
-
Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression
Gene Therapy (2004)
-
Antisense DNAs as targeted genetic medicine to treat cancer
Archives of Pharmacal Research (2003)